ImmuPharma (LON:IMM) Shares Up 27.3% – Should You Buy?

ImmuPharma plc (LON:IMM) shares shot up 27.3% on Saturday . The stock traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). 4,543,810 shares were traded during trading, a decline of 46% from the average session volume of 8,432,391 shares. The stock had previously closed at GBX 9.90 ($0.13).

ImmuPharma Trading Up 27.3%

The company has a market capitalization of £63.34 million, a P/E ratio of -1,415.73 and a beta of 1.53. The firm’s 50 day moving average price is GBX 7.92 and its two-hundred day moving average price is GBX 4.39.

ImmuPharma (LON:IMM) last released its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.